Human CST11 activation kit by CRISPRa

CAT#: GA115425

CST11 CRISPRa kit - CRISPR gene activation of human cystatin 11



  See Other Versions

CNY 12255.00


货期*
4周

规格
    • 1 kit

Product images

推荐一起购买 (3)
Rabbit polyclonal CST11 antibody
    • 100 ul

CNY 1999.00
CNY 3280.00


CST11 (Myc-DDK-tagged)-Human cystatin 11 (CST11), transcript variant 2
    • 10 ug

CNY 1200.00
CNY 3705.00


CST11 Antibody - N-terminal region
    • 100 ul

CNY 5250.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol CST11
Locus ID 140880
Kit Components

GA115425G1, CST11 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA115425G2, CST11 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA115425G3, CST11 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Reference Data
RefSeq NM_080830, NM_130794
Synonyms CST8L; CTES2; dJ322G13.6; SC13
Summary The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions. The cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes. This gene is located in the cystatin locus and encodes an epididymal-specific protein shown to have antimicrobial activity against E. coli. Alternative splicing yields two variants encoding distinct isoforms. [provided by RefSeq, Sep 2014]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...